Press Releases

Back to previous page

ReGen Biologics Meniscus Data To Be Presented

FRANKLIN LAKES, NJ -- May 8, 2006 -- ReGen Biologics, Inc. (OTC:RGBI) today announced an important podium presentation to be made at next week’s 25th Annual Arthroscopy Association of North America (AANA) meeting in Hollywood, Florida.

The presentation, titled Tissue Gain after Arthroscopic Placement of a Collagen Meniscus Implant (CMI) Following Partial Medial Meniscectomy will be given by William G. Rodkey, D.V.M. at the meeting on Friday, May 19.  Additional authors on the presentation are J. Richard Steadman, M.D., William Montgomery, III, M.D., Karen Briggs, M.P.H., and Scott Hormel, M.D.

Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive Officer of ReGen Biologics commented, “Tissue gain is an important contributor to successful return to function and activity following meniscus knee surgery.  We believe these are the first data to show tissue growth following placement of a scaffold material.”

About ReGen Biologics, Inc.
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery.  The Company’s first approved product using its collagen scaffold technology is the CMI™, a meniscus application of its collagen scaffold technology, which is cleared for sale in Europe and marketed through the Company’s European subsidiary ReGen Biologics AG.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its collagen scaffold products in its ISO Certified facility located in Redwood City, CA.  For more information on ReGen, visit www.regenbio.com.

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of the management of ReGen and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2005 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services, and at the Web site maintained by the SEC at http://www.sec.gov.

Contacts:
ReGen Biologics, Inc.
Brion Umidi
Chief Financial Officer
(201) 651-3515
bumidi@regenbio.com

Cameron Associates
Al Palombo
Investor Relations
(212) 554-5488
al@cameronassoc.com

 For Meeting Information:
Arthroscopy Association of North America  www.aana.org